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Abstract
Dysregulation of the PI3K-AKT-mTOR signaling network is a prominent feature of breast 
cancers. However, clinical responses to drugs targeting this pathway have been modest, possibly 
due to dynamic changes in cellular signaling that drive resistance and limit drug efficacy. Using a 
quantitative chemoproteomics approach we mapped kinome dynamics in response to inhibitors of 
this pathway and identified signaling changes that correlate with drug sensitivity. Maintenance of 
AURKA after drug treatment was associated with resistance in breast cancer models. Incomplete 
inhibition of AURKA was a common source of therapy failure and combinations of PI3K, AKT or 
mTOR inhibitors with the AURKA inhibitor MLN8237 were highly synergistic and durably 
suppressed mTOR signaling resulting in apoptosis and tumor regression in vivo. This signaling 
map identifies survival factors whose presence limits the efficacy of targeted therapies and reveals 
a new drug combination to unlock the full potential of PI3K-AKT-mTOR pathway inhibitors in 
breast cancer.
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INTRODUCTION
Mutations and aberrant signaling of the PI3K–AKT–mTOR pathway (PI3K-pathway) is a 
prominent feature of breast and many other cancers. Genomic alterations of PI3K-pathway 
components, including PTEN, PIK3CA, and AKT1 occur in over 60% of breast 
malignancies1. Despite this high prevalence, drugs targeting this pathway have demonstrated 
only modest responses across numerous clinical trials2,3. The clinical observation that most 
breast cancers fail to respond suggests that additional factors modulate cellular response and 
drive resistance. A prominent feature of this pathway is drug-induced signaling adaptation 
and feedback mechanisms resulting in suboptimal drug responses4–6. Therefore, it is likely 
that understanding and targeting these dynamic changes in signaling will be important in 
optimizing this class of agents.
In principle, the measurement of dynamic changes elicited by therapy can be used to develop 
novel drug combinations. While previous efforts have focused on acute signaling changes 
leading to pathway reactivation and drug resistance4,7, systematically contrasting global 
signaling changes with drug efficacy has not been performed. Such an analysis may reveal 
survival factors whose suppression is required for drug efficacy and hence could reveal new 
combinatorial strategies to enhance therapeutic responses. Previous identification of such 
factors have led to the understanding that drug-induced activation of apoptotic machinery8,9 
and impairment of protein synthesis10 is required for sensitivity to a wide variety of drugs. 
In the context of breast cancer, multiple efforts in the field have identified mTORC1 as a 
survival factor whose suppression is necessary for PI3K-pathway inhibitor sensitivity11,12. 
This observation has led to clinical trials combining PI3K and mTOR inhibitors, yet reported 
clinical results have yielded suboptimal outcomes due to increased systemic toxicity and 
cytostatic tumor effects3. Hence, there remains a pressing need to uncover new combination 
targets in order to improve therapeutic efficiency of PI3K-pathway inhibitors. Identifying 
additional survival factors will require a comprehensive understanding of signaling 
dynamics in response to treatment and insight as to how these dynamics contribute to drug 
resistance.
Little is known about global kinome rewiring in response to drug treatment, which is due in 
part to limitations in available technologies. Recently, a kinase enrichment strategy has been 
developed using a chemoproteomics technique that combines kinase affinity capture with 
quantitative mass spectrometry (MS). This approach uses a multiplexed set of type I kinase 
inhibitors immobilized onto beads (MIBs), which are used to affinity purify a diverse set of 
active kinases through their increased avidity for ATP compared to inactive kinases. 
Enriched kinases are then identified and quantified by LC MS/MS (MIBs/MS), enabling 
simultaneous measurement of many endogenous kinases based on their activity state and 
abundance7. Because many drugs impinge on common pathways and cell lines often display 
unique behaviors, it is possible that a quantitative map of kinase dynamics spanning multiple 
cell lines and drug treatments may be used to identify more general responses to drug 
treatment that are linked to drug sensitivity.
Here we applied the MIBs/MS approach to identify signaling changes associated with drug 
efficacy by mapping the kinome following exposure to targeted therapies across a panel of 
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breast cancer cell lines of various subtypes and genotypes. Comparing kinome activity 
profiles between drug-sensitive and resistant cells allowed us to generate a kinome-response 
signature associated with drug sensitivity. By performing a systematic analysis of signaling 
dynamics following drug treatment, we identified that failure to inhibit AURKA was 
associated with resistance to a diverse set of targeted therapies. Further analysis revealed that 
inhibition of AURKA was sufficient to engender strong synergistic responses when 
combined with inhibitors of PI3K, AKT, or mTOR. This provides an effective new 
framework for the unbiased identification of survival factors acting as molecular barriers to 
the efficacy of drugs, and we demonstrate the utility of this approach by developing rational 
combination strategies to enhance responses to PI3K-pathway inhibitors in breast cancer.
RESULTS
Generation and analysis of a dynamic kinome signaling map
We applied an unbiased proteomic strategy to measure kinome rewiring in response to drug 
treatment. Kinome profiling was performed via a chemoproteomics approach using 
Multiplexed Inhibitor Beads (MIBs) coupled with mass spectrometry (MIBs/MS). Our 
library of Multiplexed Inhibitor Beads (MIBs) consist of a mixture of sepharose beads 
covalently linked to 12 kinase inhibitors ranging from moderately selective (e.g. Lapatinib, 
Sorafenib) to pan-kinase inhibitors (e.g. Purvalanol B, Staurosporine) for broad kinome 
coverage (Fig. 1a and Supplementary Fig. 1). Because type I kinase inhibitors preferentially 
bind kinases in their active conformation, kinase capture by MIBs under the stringent 
binding conditions used here is a function of kinase expression, the affinity of kinases for the 
immobilized inhibitors, and the activation state of the kinase13. Vehicle or drug treated cell 
lysates were incubated with MIBs, and enriched kinases were eluted and quantified by LC 
MS/MS using label-free quantitation (see Methods)14. We estimate that our current approach 
is able to capture roughly 35% of highly expressed kinases in a given sample 
(Supplementary Fig. 2).
We applied this strategy to a panel of breast cancer cell lines of various subtype and 
genotype classifications, and measured kinome dynamics following treatment with a panel 
of targeted therapies. Cell lines were chosen to maximize transcriptional diversity and span 
the major subtypes of breast cancer (Supplementary Fig. 3). All lines harbored mutations in 
PI3K-pathway genes including PIK3CA-mutant MCF7 (ER+/PR+), BT20 (receptor 
negative) and T47D (ER+/PR+); PTEN-null BT549 (receptor negative); and HER2-amplified 
SKBR3 (HER2+) (Supplementary Fig. 4a). Cell lines were treated for 24 hours with DMSO 
or kinase inhibitors relevant to breast cancer signaling including the EGFR/HER2 inhibitor 
Lapatinib (200nM), the pan-Class I PI3K inhibitor GDC-0941 (250nM), the AKT inhibitor 
MK2206 (250nM), and the MEK inhibitor PD0325901 (100nM), and then profiled using 
MIBs/MS (Fig. 1a and Supplementary Fig. 4b). All together, we quantified changes across 
151 kinases in total and 75 kinases which were present in over 75% (15/20) of samples (Fig. 
1b, Supplementary Dataset 1). Significant drug-induced changes (defined based on the log2 
fold change of drug versus DMSO treatment, logFC) were detected for 99 kinases at 
p<0.001 corresponding to 66% of kinases measured, indicating that the drugs had 
widespread and significant impacts on global kinome dynamics.
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To assess quality and reproducibility of the MIBs/MS data, we initially compared biological 
replicates of SKBR3 (HER2+) cells treated with the dual EGFR/HER2 small-molecule 
inhibitor Lapatinib. We observed a high correlation of 0.78 between replicates for identified 
kinases (p=5e-26) (Fig. 1c). The MIBs/MS screening strategy also accurately captured 
activity inhibition of direct drug targets by Lapatinib indicated by the significant decrease in 
levels for EGFR (logFC=−5.8, p=6e-5) and HER2 (−0.7, p=1e-4) (Fig. 1c). We observed a 
decrease in MEK1 activity upon treatment with the MEK inhibitor PD0325901 in BT549 
and MCF7 cells (logFC=−1.8 and −1.2 respectively, Fig. 1d). We also observed indirect 
pathway-specific events, such as a decrease in the activity of the mTOR effector kinase 
RPS6KB1 when treated with either the PI3K inhibitor GDC-0941 or AKT inhibitor 
MK2206 in MCF7 cells (logFC=−3.5 and −2.3 respectively, Fig. 1e). Comparison of 
observed kinome changes with previous MIBs/MS data revealed a high degree of 
concordance (Supplementary Fig. 5)15. These results highlight the reproducibility of the 
MIBs/MS approach as well as its ability to identify direct and indirect drug targets based on 
reductions in both activity and abundance.
We hypothesized that the identification of shared responses across lines and drugs may lead 
to a more robust understanding of signaling dynamics, as opposed to changes specific to a 
particular drug or cell type. We therefore sought to identify changes that were generally 
associated with treatment sensitivity or resistance in a drug-agnostic fashion. First, cell lines 
were classified as sensitive or resistant to each of the drugs in our panel based on dose-
response analysis (Supplementary Fig. 4b, Supplementary Fig. 6a-d). Next, fold changes for 
each kinase were compared between these sensitive and resistant classifications for all drugs 
pooled together to identify candidate kinases whose inhibition was associated with drug 
sensitivity (Fig. 1f). This analysis revealed that suppression of 12 kinases was significantly 
associated with drug sensitivity (p<0.05). Among the identified candidates were kinases 
involved in cell cycle processes including mitotic kinases AURKA (p=0.0001) and CDK1 
(p=0.04), and kinases involved in interphase, CDK4 (p=0.02) and CDK2 (p=0.05). Other 
kinases identified were involved in YAP signaling (STK4, p=0.01) and WNT signaling 
(GSK3B, p=0.005 and CSNK1E, p=0.02). These results were not linked to general 
impairment of the cell cycle per se. We observed no correlation with sensitivity for other 
cyclin-dependent kinases (CDKs) measured in our screen such as CDK6, a closely related 
CDK to CDK4. In addition, the AURKA paralog AURKB was not significantly associated 
with sensitivity even though it is regulated during mitosis in a similar manner (Fig. 1f)16. We 
performed a similar analysis using a three-response categorization (i.e., sensitive, 
moderately sensitive, and resistant) and found that these results were largely independent to 
how sensitivity was classified (Supplementary Fig. 6e-g). We postulate that this drug-
agnostic approach identifies changes that are general to drug sensitivity and reveals factors 
that may be missed by studies limited to a single drug analyses. For example, the top 
candidate from our analysis, AURKA, was trending towards but not found to be significantly 
associated with resistance or even among the top several candidates with any single drug. 
However, by pooling responses across all drugs it emerged as the most associated with 
resistance in terms of both magnitude and significance (Supplementary Fig. 7). Therefore, 
by performing a systematic screen of signaling dynamics following drug exposure, we 
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identified a set of specific kinases whose maintenance was associated with resistance to 
targeted therapies in breast cancer.
AURKA associates with PI3K and AKT inhibitor resistance
We focused our validation of molecular correlates of drug sensitivity on the PI3K-pathway 
given its central importance to breast cancer. We observed a significant association between 
maintenance of AURKA after treatment and drug resistance (Fig. 2a). To confirm this result, 
we measured molecular responses to treatment with the pan-PI3K inhibitor GDC-0941 in 
two sensitive (T47D and MCF7, IC50 < 200nM) and two new cell lines that were robustly 
resistant (HCC38 and MDAMB453, IC50 > 40μM). A critical output of the PI3K-pathway is 
the activation of the mTORC1 complex, whose inhibition is necessary for sensitivity to PI3K 
inhibitors11. After treatment we observed suppression of mTORC1 activity only in sensitive 
cells, as evidenced by decreased phosphorylation of its effector protein S6 (Fig. 2b). 
Confirming our MIBs/MS data, in response to treatment we observed decreases in the 
abundance and auto-phosphorylation of AURKA in sensitive cells, whereas resistant cells 
maintained these levels throughout (Fig. 2b, Supplementary Fig. 9a,b). Similar results were 
observed using the AKT inhibitor MK2206, representing the next step in the PI3K-pathway 
(Supplementary Fig. 9c-e). These results confirm that failure to suppress AURKA activity is 
associated with resistance to PI3K and AKT inhibition in breast cancer cells.
We next asked how AURKA is regulated in response to PI3K-pathway inhibition in drug-
sensitive cells. AURKA regulates centrosome alignment, mitotic spindle formation and 
chromosome segregation during mitosis and its activity and abundance is tightly regulated16. 
We observed a robust and significant change in AURKA protein levels after 24 hours in 
drug-sensitive cells leading us to hypothesize that changes in transcription of AURKA might 
account for its loss after treatment. AURKA mRNA levels were decreased in response to 
GDC-0941 and MK2206 when comparing drug-sensitive and resistant cell lines (p=2.8e-5 
and p=0.004 respectively, Fig. 2c,d). In addition, transcriptomes of MCF7 and T47D cells 
treated with the PI3Kα-specific inhibitor BYL719 for 24 hours17 reflected a significant 
reduction of AURKA after drug treatment in both of these BYL719-sensitive cell lines (IC50 
≤ 250nM, Supplementary Fig. 10a)11,18. Interestingly, Gene Set Enrichment Analysis 
(GSEA)19 of these transcriptomes revealed that a prominent component of response to PI3K 
inhibition was the suppression of genes involved in the G2/M checkpoint, including 
AURKA, suggesting that transcriptional control of this aspect of the cell cycle is a major 
output of the PI3K-pathway (Fig. 2e, Supplementary Fig. 10b, Supplementary Dataset 2).
AURKA mediates survival during PI3K-pathway inhibition
We next asked if the downregulation of AURKA was functionally relevant and whether the 
presence of AURKA limits efficacy of PI3K-pathway directed therapies. We tested whether 
AURKA inhibition was sufficient to confer sensitivity to PI3K-pathway inhibitors using a 
combination profiling approach to measure drug synergy across an extended panel of 13 
breast cancer cell lines. We applied a dose matrix of increasing concentrations of the 
AURKA-specific inhibitor MLN8237 alone and in combination with a PI3K (GDC-0941), 
AKT (MK2206), or mTOR (RAD001) inhibitor and measured effects on cell proliferation. 
To evaluate drug synergy we: (1) visualized Loewe excess values, (2) scored combination 
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index values measuring shifts in drug potency, (3) calculated synergy scores based on Loewe 
excess values, and (4) visualized and scored combinations using a Bliss independence 
model20 (see Methods). Our results in MCF7 cells indicated that MLN8237 in combination 
with GDC-0941, MK2206 or RAD001 was synergistic using all four approaches (Fig. 3a, 
Supplementary Fig. 11-13, Supplementary Dataset 3). Testing the combination with 
GDC-0941 across the extended panel of cell lines we found significant synergy based on the 
Loewe excess model in 38% of models (5/13) based on a synergy score > 1, which we 
determined through simulation to represent a less than 5% chance of non-synergy (i.e. 
FDR<5%) (Fig. 3b, Supplementary Fig. 11). We extended this analysis to drug combinations 
of MLN8237 with either MK2206 or RAD001 and found significant synergy in 54% and 
85% of models, respectively (Fig. 3b, Supplementary Fig. 12,13). Overall we found no 
significant trend towards synergy based on PIK3CA or PTEN mutational status, but did 
observe slightly increased synergy in receptor positive cell lines (ER+ or HER2+, p=0.04 for 
GDC-0941 and p=0.035 for MK2206, based on a two-tailed t-test) (Supplementary Dataset 
3).
Since PI3K-pathway inhibitors are primarily cytostatic5,21 and AURKA is known to regulate 
apoptosis22, we next asked whether AURKA inhibition could enhance responses to PI3K-
pathway inhibitors by inducing cytotoxic responses. Across 12 cell lines, we found that the 
addition of MLN8237 caused an increase in apoptotic cell death (Fig. 3c), which was 
independent of the particular dose used (Supplementary Fig. 14a,b). This enhancement in 
cell death generally occurred in conditions where synergy was also observed 
(Supplementary Fig. 14b). We compared this response with the combination of CDK4/6 and 
PI3K inhibitors which are known to be synergistic12. While we observed synergy between 
PI3K, AKT and mTOR inhibitors and the CDK4/6 inhibitor LEE011, the response was 
primarily cytostatic indicating that CDK4 is only necessary for proliferation rather than 
tumor cell survival in the presence of PI3K-pathway inhibitors (Supplementary Fig. 14c-e, 
Supplementary Dataset 3). Therefore, AURKA mediates cellular survival in the context of 
PI3K-pathway inhibition, and since the drug combinations are synergistic in inducing 
apoptosis in breast cancer cells, we propose that it may be a promising companion target in 
order to enhance the efficacy of PI3K-pathway inhibitors.
MLN8237 and Everolimus (RAD001) induce cell death in vivo
We next evaluated the efficacy of this combination in vivo and focused on the combination 
of MLN8237 with the only FDA-approved inhibitor targeting this pathway in breast cancer, 
the mTOR inhibitor RAD001 (Everolimus). Clinically, RAD001 overwhelmingly results in 
disease stabilization rather than regression23. This is reflected in vitro where all lines have a 
high RAD001 Emax indicating cytostatic effects. In particular, MCF7 cells have a high Emax 
of 0.54 and do not display evidence of PARP cleavage at high doses (Supplementary Fig. 
15). To investigate whether AURKA suppression enhances response to RAD001 treatment, 
we tested the combination in MCF7 orthotopic transplants. While RAD001 or MLN8237 
monotherapy only partially impaired tumor growth, the combination showed significantly 
greater tumor growth inhibition than either single agent alone (Fig. 4a). Furthermore, all 
animals receiving the combination (9/9) showed marked tumor regression, while no 
regressions were observed with monotherapy (0/13 in total, p=2e-6 by Fisher’s exact test, 
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Fig. 4b). Post-treatment tumor specimens displayed an induction of apoptosis specific to the 
combination as demonstrated by an increase in the number of TUNEL-positive cells (Fig. 
4c,d). During the course of study we did not observe any significant weight loss in animals 
receiving the combination as compared to the RAD001 single-agent group (Supplementary 
Fig. 16), suggesting tolerability and no added toxicity from co-inhibiting Aurora kinase A. 
Therefore, the addition of MLN8237 to RAD001 treatment results in tumor regression and a 
strong cytotoxic response in vivo.
Co-inhibition durably suppresses mTORC1 signaling via AKT
We next turned to identify mechanisms driving the increased efficacy of the drug 
combination. Since most PI3K-pathway inhibitors (including rapamycin or RAD001) elicit 
feedback signals resulting in incomplete suppression of mTOR and drug resistance11,24, we 
first asked if the combination of MLN8237 enhanced the activity of RAD001 on mTOR 
signaling to effectors, RPS6 (S6) and 4E-BP1, in vivo. While we observed an incomplete 
and partial suppression of S6 in RAD001-treated MCF7 xenografts, the addition of 
MLN8237 resulted in a durable and complete loss of S6 in all 9 tumors (Fig. 5a). Though 
RAD001 is a relatively potent inhibitor of S6, it is a weak inhibitor of 4E-BP1 and therefore 
only partially impairs cap-dependent protein synthesis24. We therefore investigated the 
activity of phospho-4E-BP1, which can be stimulated by rapamycin treatment24. While 
phospho-4E-BP1 levels were enhanced with RAD001 single-agent treatment, co-treatment 
with MLN8237 suppressed these levels back to nearly baseline (Fig. 5a). This surprising 
finding led us to ask how Aurora kinase inhibition might alter this key signaling output of 
mTOR. We investigated AKT activity via phosphorylation of serine 473, which activates 
mTOR and is catalyzed by a variety of kinases25. Single-agent MLN8237 reduced phospho-
AKT levels both in monotherapy and combination treatment, indicating that Aurora kinases 
sustain mTOR levels by promoting AKT activity (Fig. 5a). We next examined whether 
Aurora kinase driven maintenance of mTOR was a general feature of PI3K-pathway 
inhibitors. Using MCF7 cells in vitro, we observed that MLN8237 treatment impaired 
phospho-AKT and that the combination of MLN8237 with either GDC-0941 (targeting 
PI3K) or MK2206 (targeting AKT) led to robust ablation of phospho-S6 and phospho-4E-
BP1 levels (Fig. 5b). Therefore, Aurora kinases contribute to resistance to PI3K-pathway 
inhibitors through the maintenance of AKT and residual mTORC1 activity. Hence targeting 
this survival mechanism results in a more durable and complete repression of the PI3K-
pathway.
Co-inhibition unbalances pro- and anti-apoptotic factors
Since we observed cell death in response to these drug combinations (Fig. 5b, Fig. 4d), we 
next sought to elucidate how Aurora kinase mediates cell survival in response to PI3K-
pathway suppression. Both Aurora kinases and mTOR regulate a number of components of 
the intrinsic apoptosis pathway22,26, and we hypothesized that deregulation of the balance of 
pro- and anti-apoptotic factors may cause cell death in response to drug combinations 
containing MLN8237. BAX promotes apoptosis while BCL2 prevents apoptosis by 
inhibiting the activity of BAX and together the balance of these two proteins forms a 
molecular rheostat for apoptosis27. In MCF7 xenografts, combination treatment resulted in 
increased BAX levels and a reduction in BCL2 levels leading to an increase in the ratio of 
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BAX/BCL2 compared to either MLN8237 or RAD001 treatment alone (Fig. 5c). 
Furthermore, the BAX/BCL2 ratio was also increased by the addition of MLN8237 to 
GDC-0941, MK2206 or RAD001 in MCF7 cells in vitro where it was associated with the 
presence of cleaved PARP (Fig. 5b,d). Taken together, we propose a model whereby Aurora 
kinase inhibitors potentiate the activity of PI3K-pathway inhibitors through enabling a 
durable and complete suppression of AKT/mTOR signaling, and drive cell death by altering 
the balance of pro and anti-apoptotic factors (Fig. 5e).
MYC regulates AURKA downstream of the PI3K-pathway
We next sought to identify factors that regulate AURKA in response to treatment. We noted 
that a MYC target gene signature was among the most suppressed gene sets after treatment 
with BYL719 suggesting MYC may play a significant role in regulating the transcriptional 
response to PI3K inhibition and therefore potentially AURKA (Fig. 2e). To directly define if 
MYC activity is suppressed by PI3K-pathway inhibition, we transcriptionally profiled an 
isogenic pair of MCF10A breast epithelial cells over-expressing MYC to derive a gene 
signature of the top 150 most up-regulated genes by MYC (Supplementary Dataset 4). 
Comparison of this signature with transcriptional changes induced by BYL719 treatment in 
MCF7 and T47D cells revealed that most MYC signature genes were strongly repressed 
during PI3K inhibition (Fig. 6a,b). Therefore MYC is regulated by the PI3K-pathway in 
these cells, likely via mTORC1-mediated translation and AKT-mediated stabilization of 
MYC28–30. AURKA was among the signature genes and we found that MYC over-
expressing cells had an 8-fold increase in AURKA transcript levels as well as higher levels 
of total and phosphorylated AURKA protein (Fig. 6c,d). These data provide direct evidence 
that MYC regulates AURKA abundance and activity and suggest that both are controlled by 
the PI3K-pathway in breast cancer.
Considering AURKA activates AKT (Fig. 5b)31,32, our results suggest a model whereby the 
PI3K-pathway regulates the abundance of its upstream activator AURKA through the 
control of MYC. Hence, MYC-driven AURKA signaling may constitute a positive feedback 
loop that helps to continuously activate the PI3K-pathway, even in the context of single 
agent drug treatment. In support, we observed that MCF10A-MYC cells were more resistant 
to GDC-0941 and MK2206 compared to parental cells consistent with previous reports of 
MYC driving resistance to inhibitors of this pathway (Fig. 6e,f, Supplementary Fig. 
19a,b)33–36. Although MYC expressing cells were drug-resistant, they could be re-sensitized 
to GDC-0941 or MK2206 by the addition of MLN8237 back to approximately the same 
relative IC50 as parental cells given the combination (Fig. 6e,f, Supplementary Fig. 19a,b), 
indicating that AURKA is principally responsible for causing the resistance to PI3K 
inhibition seen as a result of MYC activation in this model.
To test this model, we asked if MYC-driven resistance to PI3K inhibitors is through the 
maintenance of PI3K-pathway activity and if this is dependent on AURKA. GDC-0941 
treatment in MCF10A cells led to a reduction in MYC and AURKA signaling as well as 
phospho-S6 and phospho-4E-BP1, indicating that MYC and AURKA are regulated by the 
PI3K-pathway (Fig. 6g). However, constitutive expression of MYC resulted in the 
maintenance of all of these factors after PI3K inhibition suggesting that MYC also acts 
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upstream of the PI3K-pathway and can maintain its activity. Furthermore, maintenance of 
mTORC1 signaling by MYC over-expression was reversed by co-inhibition of AURKA thus 
designating AURKA as the critical link between MYC and activation of the PI3K-pathway 
in these cells (Fig. 6g). Similar results were observed using the AKT inhibitor MK2206 
(Supplementary Fig. 19c). Taken together, our data define a novel circuit whereby the PI3K-
pathway regulates the abundance of its own activator through MYC-mediated transcription 
of AURKA (Fig. 6h).
DISCUSSION
Through an unbiased proteomics approach to assay kinase activity, we measured dynamic 
changes elicited by therapy as a means to develop novel drug combinations. The systematic 
measurement of kinome dynamics across a diverse set of cell lines allowed us to map 
molecular changes associated with resistance to a variety of inhibitors, which is unique from 
previous approaches limited to a single drug or cell line7,15,37. We found a number of cases 
where failure to inhibit a particular kinase was associated with drug resistance. Since our 
proteomic screen included multiple drugs that impinge on distinct oncogenic pathways, we 
found it surprising that a set of common survival factors were identified. This may be due to 
the convergence of both the PI3K and MAPK pathways on protein synthesis38,39. Beyond 
AURKA, we identified that CDK4 suppression was associated with drug sensitivity and that 
the combination of CDK4 and PI3K-pathway inhibitors was synergistic, consistent with 
previous work12. Future work may determine if other candidates we identified also act as 
survival factors and how they might do so.
We show that the expression of AURKA limits the efficacy of PI3K-pathway targeted 
therapy and thus represents a new vulnerability to enhance therapeutic responses to this class 
of drugs. Investigating AURKA regulation we found that the reduction in AURKA 
abundance in drug-sensitive cells appears to be the result of transcriptional control by MYC, 
which is in turn regulated by the PI3K-pathway. MYC has been shown to regulate AURKA 
transcription in multiple tumor types40-42. MYC has been associated with resistance to PI3K 
inhibitors which may be clinically relevant but remains mechanistically ambiguous33–36. 
Here we show that one potential mechanism of resistance is through MYC-driven AURKA 
activation resulting in maintenance of the PI3K-pathway in response to PI3K inhibition. 
Future work may gauge the relative importance of AURKA versus other outputs of MYC in 
driving resistance to PI3K inhibitors.
Maintenance of AURKA was sufficient to confer drug resistance in a variety of cell lines as 
evident by the widespread drug synergy we observed. We show that in response to treatment 
with PI3K-pathway inhibitors Aurora kinase maintains the activation of AKT and drives 
residual mTOR activity. Co-inhibition of the PI3K-pathway and AURKA with MLN8237 
fully blocks this residual mTOR activity resulting in cell death. These findings also highlight 
the importance of AKT activation through serine 473 as a route of drug resistance. Since a 
number of kinases have been shown to operate at this site including mTORC225, it remains 
unclear whether Aurora kinases act on this site directly or indirectly. These studies elaborate 
a positive feedback loop whereby the PI3K-pathway promotes the expression of AURKA, 
which in turn activates the pathway via AKT. One feature of such a positive feedback loop is 
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the creation of switch-like outputs resulting in heightened stability and resistance to 
perturbation43. We postulate that such loops are common and may lead to the resiliency and 
adaptation that is a hallmark of the PI3K-pathway and a major cause of the challenges in 
targeting it therapeutically. Delineating such loops may be an important strategy in 
identifying effective drug combinations. As a case in point, we show that eliminating this 
positive feedback loop by blocking AURKA renders cells more sensitive to PI3K inhibitors.
Our findings reveal that the combination of Aurora kinase inhibitors and PI3K-pathway 
inhibitors is synergistic and could be a promising clinical strategy to enhance treatment 
response in breast cancer. These data are consistent with observations made in other 
settings44–46. Clinical data of PI3K and mTOR inhibitors have shown only modest benefit in 
breast cancers, at best resulting in short term disease stabilization in patients23,47. Consistent 
with these clinical observations, most inhibitors in this class cause only a proliferative arrest 
in vitro5,21 and it has been proposed that combinations that induce apoptosis may be used to 
enhance responses48. In contrast to cytostatic combinations with the CDK4/6 inhibitor (i.e. 
synthetic sickness), we found that combinations with Aurora kinase inhibitors were 
synergistic and potently induced cell death. As clinical trials testing CDK4/6 inhibitor 
combinations are ongoing, it remains to be seen the impact this distinction will play on 
patient responses. These results warrant an expanded analysis of combinations with AURKA 
inhibitors in additional patient-derived models of breast and other cancer types. Tested as 
monotherapy, Aurora kinase inhibitors have reached phase 3 clinical trials for lymphoma 
with manageable toxicities but limited efficacy49. Given that the most common adverse 
events of PI3K-pathway inhibition are hyperglycemia, rash, and gastrointestinal toxicity, and 
those of Aurora kinase inhibition are primarily neutropenia, we are encouraged that the non-
overlapping toxicity profile between the two agents may be tolerated in patients as they were 
in our in vivo studies. As single-agent responses to both PI3K-pathway and Aurora kinase 
inhibitors have been modest, these findings may unlock the full potential of these agents in 
realizing a clinical benefit.
ONLINE METHODS
Breast cancer cell lines and reagents
BT549 and SKBR3 cells were obtained from the UCSF Cell Culture Facility. BT20, BT474, 
HCC1428, HCC38, LY2, MCF7, MDAMB231, MDAMB453, T47D, SUM52PE, and 
ZR75B cell lines were obtained from the American Type Culture Collection (ATCC). Cell 
lines used for proteomic profiling and molecular analyses were authenticated by STR 
analysis. Lines were grown according to published protocols50 except for SKBR3 which was 
cultured using RPMI media supplemented with 10% fetal bovine serum (FBS) and 1% pen/
strep. All cell lines tested negative for mycoplasma contamination. Drugs used for cell 
culture experiments in this study were purchased from Selleck Chemicals (GDC-0941, 
MK2206, PD0325901, Lapatinib, MLN8237, and LEE011) and LC Laboratories (RAD001).
Multiplex inhibitor bead (MIB) analysis
Multiplexed Inhibitor Bead enrichment and MS analysis (MIBs/MS) were performed as 
described previously14. In summary, a selection of bait compounds were purchased or 
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synthesized and immobilized on sepharose using standard peptide coupling chemistry. The 
following compounds were purchased commercially: Bisindolylmaleimide X (Enzo Life 
Sciences); SB202190, Staurosporine (LC Labs); Purvalanol B (Tocris); Lapatinib, 
Crizotinib, Dasatinib (Selleckchem). When not commercially available without 
modification, linkable versions of previously described compounds were synthesized based 
on prior methods: VI-1683251,52, Akti-4653, PP-hydroxyl54, sorafenib55, and JG-456 with 
minor adjustments made for synthetic tractability. After initial pilot syntheses and validation, 
compounds were synthesized by Pharmaron, Inc. Louisville KY. Couplings were performed 
overnight at room temperature on a rotator. Beads and compounds were mixed in 1:1 
Dimethyl formamide: Ethanol with 0.1 M 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide.
After 24-hour treatment with drug or DMSO, cell lysates were diluted in binding buffer with 
1 mol/L NaCl and kinase enrichment was performed using gravity chromatography 
following pre-clearing. After washing, the bound kinases were eluted with SDS followed by 
extraction/precipitation, tryptic digest and desalting. Liquid chromatography-tandem mass 
spectrometry (LC/MS-MS) was performed on a Velos Orbitrap (Thermo Scientific) with in-
line high-performance liquid chromatography (HPLC) using an EASY-spray column 
(Thermo Scientific). Peptide identifications were made using ProteinProspector (v5.10.10) 
and input into Skyline for label-free quantification57.
Peptide quantification data were pre-processed before analysis with MSstats v2.3.358. First, 
library peptides and peptides that map to non-kinase proteins were removed. Kinase peptide 
peak area values were log2-transformed and quantile-normalized to correct for variation 
between replicates. Finally, peptides that mapped to multiple kinases were removed, as well 
as peptides that were entirely missing in one or more conditions. For each kinase, the log2 
ratio of each drug-treated condition to the DMSO control was estimated using the mixed-
effects regression model in MSstats.
Drug combination studies
Cell lines were seeded in 384-well assay plates at a density of 1,000 cells/well in a total 
volume of 40 μL/well, and incubated at 37°C, 5% CO2 overnight. Dose matrices were 
assembled containing 6-point, 4-fold serial dilutions from the top concentration for each 
agent on the x- and y-axes. Following 72 hours of drug exposure, proliferation and cell death 
was measured by staining with Hoescht (Life Technologies) nuclear dye and YO-PRO-1 
(Life Technologies), respectively, and analyzed using a Thermo CellInsight High Content 
microscope. Raw phenotype measurements from each treated well were normalized to the 
median of vehicle-treated control wells and examined for synergistic effects between both 
compounds.
To evaluate drug combinations we used a Loewe model of drug additivity and calculated a 
synergy score. First, we fit a sigmoidal function to each of the single agent responses. Next 
we calculated the expected inhibition for each combination using the Loewe additivity 
model20. The synergy score S was calculated as previously defined59 as a positive-gated 
inhibition-weighted volume over of Loewe additivity:
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S = ln f Xln f Y∑max(0, Idata)max(0, Idata − ILoewe)
Where fX and fY are the dilution factors used for compounds X and Y respectively, Idata is 
the matrix of inhibition data at this dilution factor, and ILoewe is the expected inhibition 
according to Loewe additivity. Synergy score calculations were also derived using Bliss 
independence20, based on a model where drugs act independently of each other. CI50 values 
for equal-dose combinations were calculated as previously defined20:
CI50 =
(D)1
(D50)1
+
(D)2
(D50)2
Where (D)1 and (D)2 are the given doses of the two drugs, and (D50)1 and (D50)2 are the 
IC50 values for each drug as a single agent.
To determine a cutoff for the synergy score we simulated the distribution of scores generated 
by an additive drug combination. We generated two hypothetical compounds by sampling 
random shape parameters for their dose-response functions, and calculated the expected 
Loewe model of the combination. We then added normally distributed noise to the model 
with variance estimated from our experimental data and calculated the resulting synergy 
score. This process was repeated 100,000 times to simulate the distribution of synergy scores 
for different additive combinations. The 95th percentile of this distribution was 0.91 and so 
we conservatively identified combinations with S ≥ 1as synergistic.
Western blotting and antibodies
Proteins were extracted using RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% 
sodium deoxycholate, 0.1% SDS, 1 mM EDTA pH 8.0, 1% NP-40) containing proteinase 
(Roche) and phosphatase (Roche) inhibitor cocktails. Samples were resolved using 4–12% 
SDS-PAGE gels (Life Technologies) and transferred to PVDF membranes (Millipore). 
Membranes were probed overnight on a 4°C shaker with primary antibodies (1:1,000 
dilution unless indicated) recognizing the following proteins: p-AKT (Ser473) (9271, Cell 
Signaling), AKT (4691, Cell Signaling), p-S6 (Ser240/244) (5364, Cell Signaling, 
1:20,000), p-4E-BP1 (Thr37/46) (2855, Cell Signaling), p-AURKA (Thr288) (3079, Cell 
Signaling), AURKA (4718, Cell Signaling), Cleaved PARP (Asp214) (9541, Cell Signaling), 
BCL2 (2870, Cell Signaling), BAX (2772, Cell Signaling), MYC (ab32072, Abcam), and β-
actin (3700, Cell Signaling).
Mouse xenograft studies
All animal studies were conducted in compliance with all relevant ethical regulations set 
forth by the UCSF Institutional Animal Care and Use Committee (IACUC). 4-week old 
immunocompromised NOD/SCID female mice were purchased from Taconic Biosciences, 
and MCF7 cells used for in vivo transplant were obtained from the UCSF Preclinical 
Therapeutics Core. Xenograft tumors were initiated in the cleared mammary fat pads of 
mice bearing slow release estrogen pellets (Innovative Research of America) by orthotopic 
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injection of 1e6 MCF7 cells in a 1:1 mixture of serum-free medium and Matrigel (BD 
Biosciences). When tumors reached ≥ 1 cm in any direction via electronic caliper 
measurements, mice were randomized into cohort groups and treatment was initiated.
Treatment arms received either vehicle (1:1 mixture of single-agent diluents), RAD001 
formulated as a microemulsion (2mg/kg/q; 30% Propylene glycol, 5% Tween 80), 
MLN8237 (10mg/kg/q; 10% 2-hydroxypropyl-β-cyclodextrin, 1% sodium bicarbonate), or 
the combination daily, via oral gavage. Animals were monitored daily for evidence of 
toxicity including weight and skin effects, and changes in tumor size (mm3) through 
bidirectional measurements of perpendicular diameters using electronic calipers, and 
calculated as V = 1/2 (length ×width2). Mice were sacrificed after 15 days of treatment, 
following which tumors were excised and a portion of the tissue fixed in 4% 
paraformaldehyde. The remaining tumor tissue was flash-frozen in liquid nitrogen.
Immunohistochemical analysis
PFA-fixed tumor samples were paraffin-embedded, and immunohistochemical staining of 
tissue sections was performed. TUNEL staining was carried out using the ApopTag 
Peroxidase In situ Apoptosis Detection Kit (Millipore), according to the manufacturer’s 
instructions (n=15 data points per group; five high-powered (20×) fields analyzed from 
separate areas of each tumor from 3 mice per experimental group). Stained slides were 
digitized using the Leica DMi1 Microscope (Leica Microsystems) with a 20× objective. 
Images were scored as the number of TUNEL-positive cells per captured field, and 
quantification was performed in a manner that was blinded to treatment group.
Real-time PCR
RNA was isolated according to the manufacturer’s instructions (TRIzol, Life Technologies). 
One microgram of total RNA from each sample was subjected to first-strand cDNA 
synthesis according to the manufacturer’s recommendations (Promega). Quantitative PCR 
was performed on a CFX96 Real-Time PCR detection system with a PrimeTime Gene 
Expression Master Mix (IDT technology) according to the manufacturer’s protocol. 
AURKA was amplified with the following primers: 5′-AGTTGGCAAACGCTCTGTCT-3′ 
(forward primer) and 5′-GTGCCACACATTGTGGTTCT-3′ (reverse primer). RPL13A was 
used as an endogenous control with the following primers: 5′-
CGGATTTGGTCGTATTGG-3′ (forward primer) and 5′-TCCTGGAAGATGGTGATG-3′ 
(reverse primer). The cycling conditions for AURKA and RPL13A were as follows: one 
cycle at 95°C for 3 min; 40 cycles of 95°C for 15 s, and 60°C for 60 s. The specificity of the 
PCR amplification was validated by the presence of a single peak in the melting curve 
analyses.
Gene Set Enrichment Analyses (GSEA)
Gene set enrichment analysis (GSEA) of hallmark cancer gene signatures in the Molecular 
Signatures Database (MSigDB v6.0) was performed using GSEA v3.0 software (http://
www.broadinstitute.org/gsea/)19 under the following parameters: permutation, phenotype; 
metric, Signal2Noise; scoring scheme, weighted; and number of permutations, 1,000. Gene 
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sets were considered significantly enriched following a nominal P < 0.05 and FDR < 0.25 
cutoff.
Statistical analysis
Data are expressed as means ± s.d., unless otherwise indicated. Statistical analyses were 
performed using GraphPad Prism 6 (v6.0g) and R (v3.32). Two-tailed Student t tests (with 
unequal variance) were used in all comparisons unless otherwise noted. P < 0.05 was 
considered statistically significant throughout the study.
Data Availability Statement
All data generated or analyzed during this study are included in this published article and its 
supplementary information files. The raw mass spectrometry data is accessible via http://
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Figure 1. Measurement of kinome dynamics to identify correlates of drug sensitivity
(a) Schematic of approach using multiplex inhibitor beads followed by mass spectrometry 
(MIBs/MS). Sample lysates are passed through a column containing the indicated kinase 
inhibitors covalently linked to beads. After washing, bound proteins are eluted, trypsin 
digested and quantified through label-free mass spectrometry. (b) Human kinome tree 
annotated with kinases identified in this study and colored based on the percentage of total 
samples where each particular kinase could be quantified. (c) Comparison of activity ratios 
between biological replicates for 122 kinases, expressed as a log ratio of measurements from 
SKBR3 cells treated with 200nM Lapatinib for 24 hours versus DMSO. Pearson correlation 
and p value shown. (d) Comparison of kinase activity ratios in BT549 and MCF7 cells 
treated with 100nM PD0325901 versus DMSO. Data represent 75 kinases with one outlier 
kinase (GAK, BT549 log2 fold change 8.3) removed. (e) Comparison of activity ratios for 70 
kinases measured from MCF7 cells treated with either 250nM MK2206 or GDC-0941 
versus DMSO. (f) Categorical analysis of kinome dynamics occurring in drug-sensitive 
treatment responses (n=6) versus resistant treatment responses (n=14) for all drugs pooled 
together. For visualization purposes, each kinase was centered on the mean of resistant 
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samples. Data shown for 75 kinases which could be measured in >75% of samples. All drug 
treatments are 24 hours. Error bars are mean ± s.e.m. and p values calculated using a two-
sided t-test.
Donnella et al. Page 19
Nat Chem Biol. Author manuscript; available in PMC 2018 December 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Maintenance of AURKA is associated with resistance to PI3K inhibition
(a) Changes in activity of AURKA as measured by MIBs in drug-sensitive versus drug-
resistant treatment responses after 24 hours of exposure to the indicated compounds. Each 
point reflects a single cell line and drug treatment (n=20 biologically independent samples). 
Box-and-whisker plots show median (centerline), upper/lower quartiles (box limits), and 
whiskers spanning the interquartile range from 25-75 percentiles. P value calculated using a 
two-sided t-test. (b) Western blot showing PI3K and AURKA signaling in GDC-0941-
resistant and GDC-0941-sensitive cell lines. Protein lysates from cells treated with 1μM 
GDC-0941 were extracted at different points time, separated by SDS-PAGE, and analyzed 
by immunoblot with the indicated antibodies. Representative image of n=3 independent 
experiments (full blots shown in Supplementary Fig. 8). (c,d) Log ratio expression values of 
AURKA mRNA measured by RT-PCR from the indicated cell lines treated with (c) 1μM of 
GDC-0941 or (d) 1μM MK2206 for 24 hours and compared to DMSO treatment. Data 
represents n=3 biological replicates. Error bars are mean ± s.e.m. and p values calculated 
using one-way ANOVA. (e) Gene Set Enrichment Analysis (GSEA) of top gene sets 
significantly upregulated or downregulated after 24 hours in response to 1μM BYL719 
treatment in MCF7 and T47D cells compared to DMSO. Data in panel (e) based on 
transcriptomic data from Bosch, et al.17
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Figure 3. AURKA suppression enhances sensitivity and drives cell death in response to PI3K-
pathway inhibitors in breast cancer cell lines
(a) A dose matrix of GDC-0941 (PI3K), MK2206 (AKT), or RAD001 (mTOR) in 
combination with the AURKA inhibitor MLN8237 in MCF7 cells. Cell proliferation was 
assessed after 72 hours. Percent growth inhibition at each dose shown. (b) Synergy scores 
based on a Loewe excess inhibition model across 13 breast cancer cell lines that were treated 
with the indicated combination using a escalating dose matrix for 72 hours. Dashed line 
indicates a 5% FDR cutoff to define synergistic combinations (see Methods). (c) Cell lines 
were treated with 625nM of the indicated single agents or combined together for 72 hours 
and apoptosis measured by YO-PRO1 positivity. Data represents n=4 biologically 
independent samples. Error bars are mean ± s.d. and p values calculated using a two-sided t-
test.
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Figure 4. The Aurora kinase inhibitor MLN8237 enhances sensitivity to Everolimus (RAD001) 
and induces cell death in vivo
(a) MCF7 orthotopic xenograft tumors were treated with vehicle (n=6 biologically 
independent mice), RAD001 (2 mg/kg/day, n=7 biologically independent mice), MLN8237 
(10 mg/kg/day, n=6 biologically independent mice) or the combination of the two single-
agents (n=9 biologically independent mice) via oral gavage, daily, over 15 days. The 
percentage change in tumor volume was calculated for each animal from baseline. (b) 
Individual tumor profiles compared to baseline for each tumor treated with vehicle (n=6 
biologically independent mice), RAD001 (n=7 biologically independent mice), MLN8237 
(n=6 biologically independent mice) or the combination (n=9 biologically independent 
mice) over a 15-day period. (c) Representative images of tumor tissue extracted from mice 
after 15 days treatment with the indicated agents and stained for H&E and TUNEL. Images 
shown using a 10× objective. Scale bars represent 200 μm. (d) Quantification of the number 
of TUNEL+ cells/field from TUNEL staining of MCF7 tumors following 15 days of 
treatment. Data is an average of five high-powered (20×) fields analyzed per tumor and are 
representative of n=3 biologically independent animals. In all graphs, error bars are mean ± 
s.d. and p values calculated using a two-sided t-test.
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Figure 5. Aurora kinase co-inhibition durably suppresses mTORC1 signaling and alters the 
BAX/BCL2 ratio
(a) MCF7 orthotopic xenografts were treated with vehicle (n=6 biologically independent 
mice), RAD001 (2 mg/kg/day, n=7 biologically independent mice), MLN8237 (10 mg/kg/
day, n=6 biologically independent mice) or the combination of the two single-agents (n=9 
biologically independent mice) for 15 days, at which point tumors were harvested and snap 
frozen. Western blot of protein lysates from individual tumors were probed with the 
indicated antibodies (full blots shown in Supplementary Fig. 17a). (b) MCF7 cells were 
treated with either 250nM GDC-0941, 250nM MK2206, 5nM RAD001, 100nM MLN8237 
or the indicated combinations for 24 hours and protein lysates subjected to immunoblot 
using the indicated antibodies. Representative image from n=3 independent experiments 
(full blots shown in Supplementary Fig. 17b). (c) BAX, BCL2 and BAX/BCL2 ratio in 
MCF7 orthotopic xenografts treated for 15 days with the indicated drugs based on 
quantification of western blot images (RAD001, n=7; MLN8237, n=6; combination, n=9 
biologically independent mice analyzed). (d) BAX/BCL2 ratio in MCF7 cells treated for 24 
hours with the indicated drugs based on quantification of western blot images from n=3 
independent experiments. (e) Proposed model of mechanism of Aurora kinase inhibitor 
synergy. De novo resistance to single agent inhibition of PI3K, AKT or mTOR is due to 
incomplete suppression of the pathway due to Aurora kinase signaling which activates AKT. 
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Drug combinations that simultaneously inhibit the PI3K-pathway and block Aurora kinase 
signaling completely suppress mTOR signaling to 4E-BP1 and S6 resulting in tumor cell 
death. In all graphs, error bars are mean ± s.e.m. and p values calculated using a two-sided t-
test.
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Figure 6. AURKA transcription is regulated by MYC downstream of the PI3K-pathway
(a,b) Histogram of normalized gene expression of all 150 genes in the MYC gene signature 
compared to genes not in this signature for (a) MCF7 or (b) T47D cells treated with 1μM 
BYL719 or DMSO for 24 hours. BYL719 treatment data obtained from Bosch, et al.17 and p 
values determined by Kolmogorov–Smirnov test. (c) Relative levels of AURKA mRNA in 
an isogenic pair of control (PURO, n=3 independent samples) or MYC expressing MCF10A 
cells (n=2 independent samples) measured by RT-PCR. (d) Immunoblot of protein lysates 
from PURO or MYC cells representative of n=3 independent experiments with similar 
results (full blots shown in Supplementary Fig. 18a). (e) Proliferation of control or MYC 
cells in response to GDC-0941 or treated with the combination of 2.5nM MLN8237. 
Combinations were normalized to MLN8237 alone. Data represents n=4 biologically 
independent samples. (f) IC50 analysis of dose-response curves shown in (e) from n=4 
independent samples. (g) Immunoblot of lysates from control and MYC MCF10A cells 
treated with 1μM of GDC-0941 or 100nM of MLN8237 for 24 hours. Representative image 
of n=3 independent experiments with similar results (full blots shown in Supplementary Fig. 
18b). (h) Proposed model of positive feedback loop between the PI3K-pathway, MYC and 
AURKA. In all graphs, error bars are mean ± s.d. and p values calculated using a two-sided 
t-test, unless otherwise indicated.
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